Laurus Labs starts FY27 with record Q1 and accelerates growth capex

Laurus Labs entered FY27 with a strong first quarter and a clear investment-led growth plan. In 1Q FY27, the company reported revenue of ₹2,026 crore, up 29 percent year on year, supported by strong CDMO execution and steady momentum in Affordable Medicines. Profitability moved up faster than revenue. EBITDA rose to ₹644 crore, up 66 percent year on year, and the EBITDA margin expanded to 31.8 percent from 24.8 percent a year ago. Net profit came in at ₹368 crore, up 126 percent year on year, with net margin at 18.2 percent.

The quarter also carried an important signal about the next phase of the cycle. Laurus kept investing heavily, with capex at ₹394 crore in 1Q FY27, equal to 19 percent of revenue. This followed a multi-year buildout. From FY22 to FY26, the company invested ₹4,300 crore, mostly as growth capex, to expand capacity and add new technology platforms. Management now guides for EBITDA margins above 30 percent from FY27 onward, and 1Q FY27 is already tracking above that level.

What drove 1Q FY27: mix improvement and operating leverage

The quarter’s improvement was not only a growth story, but also a mix story. Gross margin increased to 62.7 percent in 1Q FY27 from 59.4 percent in 1Q FY26, helped by better divisional mix. That flowed through to EBITDA margin expansion, and the uplift in net profit was even sharper.

Management commentary in the presentation points to robust CDMO growth driven by commercial project supplies, while Affordable Medicines remained steady and was led by Finished Dosage Forms. The company also highlighted rising R and D intensity. Reported R and D spend was ₹118 crore, or 5.8 percent of revenue, up 74 percent year on year, reflecting development work tied to Advanced Biologics infrastructure, including gene therapy and ADC.

At a consolidated level, the quarter builds on a recovery year in FY26. For FY26, Laurus delivered revenue of ₹6,813 crore, up 23 percent, and EBITDA of ₹1,826 crore, up 64 percent, with EBITDA margin at 26.8 percent. Net profit in FY26 was ₹889 crore. The step-up in 1Q FY27 margins suggests that the FY26 rebound is carrying forward, and that the newer assets and pipeline execution are beginning to support better utilization and operating leverage.

The operating model: integrated platforms and a shifting revenue mix

Laurus positions itself as an integrated CDMO and CMO platform with two core divisions: CDMO and Affordable Medicines. The CDMO division spans small molecules across drug substance and drug product services, plus specialized modalities such as gene technology development and manufacturing, peptides, antibody drug conjugates, and precision fermentation. Affordable Medicines covers APIs and formulations with a therapy focus that includes ARV, oncology, cardio, diabetic, gastro, CNS, asthma, and ophthalmic.

A key strategic arc over multiple years has been reducing dependence on ARV. The company’s presentation shows ARV share declining from 67 percent in FY19 to 41 percent in FY26, while CDMO revenue share rose to 31 percent in FY26. This is consistent with the division-level trend in FY20 to FY26 where CDMO recorded a 33 percent CAGR with FY26 growth of 36 percent. Affordable Medicines grew at a 12 percent CAGR over FY20 to FY26 with FY26 growth of 18 percent. In FY26, Affordable Medicines still accounted for 69 percent of revenue, so this is not yet a CDMO majority business, but the direction is clear.

The CDMO small molecule engine is already meaningful. Small molecule CDMO revenue rose to ₹1,896 crore in FY26, and 1Q FY27 revenue in that line was ₹835 crore versus ₹493 crore in 1Q FY26, a 69 percent increase. The company also referenced a pipeline of more than 125 projects as of March 2026, diversified by technology, indications, and customer types. Recent highlights emphasize visibility on late-stage projects and commercial API supplies, and deeper client engagement on complex modalities and fully integrated projects from pre-clinical through drug product services.

Bio and precision fermentation is another building block. The bio business delivered FY26 revenue of ₹184 crore, with 1Q FY27 revenue of ₹35 crore, up 21 percent year on year. Management priorities include accelerating enzymatic and biocatalysis applications, increasing product development throughput, and creating commercial scale capacity. The large-scale fermentation manufacturing site in Vizag is expected to be commissioned by December 2026.

Affordable Medicines remains the scale anchor, and the narrative here is steadier rather than explosive. FY26 showed continued expansion across API and FDF. In 1Q FY27, the presentation notes that Affordable Medicines growth was led by FDF. The company is also expanding regulated market filings, with a portfolio of 92 DMFs and 96 dossiers filed across the US, EU, and Canada. Another important capacity step is the KRKA joint venture formulations site in Hyderabad, with Phase I targeted for mid-2027 and a focus on high potent and general oral solid dosage capabilities.

Capex, capacity, and the question of asset turnover

Laurus is in a heavy investment phase, and the presentation is unusually explicit about both the size of capex and the company’s own utilization metrics. The company invested ₹4,300 crore between FY22 and FY26, around 15 percent of revenue, with 85 percent categorized as growth capex. The allocation skewed toward API and CDMO at 82 percent, with 18 percent toward FDF.

The next wave is also large. Management outlined cumulative capex of more than ₹3,000 crore over FY27 and FY28, with key projects spanning API, formulations, peptides, fermentation, gene therapy, and ADC. 1Q FY27 capex of ₹394 crore at 19 percent of revenue signals that the pace is not easing.

When a company invests at this intensity, investors tend to track asset turnover and returns closely. Laurus disclosed asset turnover progression. It fell from 1.4x in FY21 to 0.8x in FY24 and FY25, before recovering to 0.9x in FY26 and 1.0x in 1Q FY27. The medium-term expectation is 1.1x, in line with its 6-year average of 1.1x.

The mix of projects suggests why asset turnover dipped and why recovery may take time. Many investments are in new platforms and higher complexity capabilities that typically require qualification, customer onboarding, and ramp-up. The presentation highlights three capex projects as representative. Unit 7 is a large-scale API facility with multiple flexible blocks, with Phase 1 starting in 2027. A commercial gene and ADC platform with fill-finish aims to be qualified by mid-2027. An enzyme fermentation plant to boost biocatalysis capacity is expected to be online by end 2026.

The key is whether revenue growth keeps pace with the asset base expansion. The company’s FY26 and 1Q FY27 growth suggests momentum is already strong, and the margin profile indicates that as utilization improves, operating leverage can be meaningful.

Balance sheet, cash flows, and execution discipline

Even with elevated capex, Laurus is showing improving cash generation. Operating cash flow increased to ₹1,624 crore in FY26, while FY26 capex was ₹1,070 crore. This combination supports the company’s plan to keep investing without overstretching leverage.

The leverage metric highlighted is net debt to EBITDA. It stood at 1.3x in FY26 and remained at 1.3x in 1Q FY27. The presentation also reports RoCE improving from 9.7 percent in FY25 to 17.7 percent in FY26 and further to 19.3 percent in 1Q FY27. The RoCE improvement aligns with margin recovery and stronger earnings, but it will still be tested against the upcoming FY27 to FY28 capex cycle.

Operationally, Laurus continues to emphasize quality and compliance as a core capability rather than a checkbox. The platform is supported by 15 manufacturing sites and 6 R and D centers, with 1,425 plus quality audits and inspections, and zero critical findings as stated in the presentation. This matters in practice because the company’s strategy relies on serving regulated markets and being trusted with complex and high value programs.

Technology platform expansion and ESG commitments

The company is positioning its manufacturing and technology platform as broad and scalable. The listed capabilities include small molecule, high potency, flow chemistry, continuous drug product, bio catalysis, peptide, spray drying, cell and gene, and ADC. The company also reports 1,570 plus scientists, and an integrated solution from API to formulations at scale with global regulatory approvals.

Advanced Biologics is still in build mode, but management is making it a visible part of the story. In gene therapy and ADC, Laurus has in-licensed two ADC assets from Aarvik Therapeutics for development and commercialization in India markets, and is building an integrated facility spanning process development, bioconjugation, and finished ADCs. Qualification is expected by end 2027. In cell therapy, the company reported more than 660 infusions as of June 2026, and a second GMP production facility in Navi Mumbai operationalized in March 2026 with capacity to produce 2,500 plus treatments.

ESG is framed through specific targets and third-party recognition. Laurus confirmed SBTi validated targets with Scope 1 and 2 absolute reduction of 42 percent by FY31 versus FY25 and Scope 3 intensity reduction of 51.6 percent by FY31 versus FY25. The roadmap also states that more than 50 percent electricity will come from renewable sources by 2031 via PPA for all sites. Recognition cited includes ecoVadis Silver Top 15 percent in June 2026, MSCI ESG rating of BBB, and an S and P Global ESG score of 81 out of 100.

Investor takeaways: a strong start, and a capacity story still unfolding

The September 2026 investor presentation reads like a company moving from a single-engine past toward a multi-platform future. 1Q FY27 showed that the earnings rebound of FY26 is continuing, with record quarterly revenue, strong mix, and margin expansion. CDMO appears to be doing more of the heavy lifting, while Affordable Medicines provides scale and stability.

The next two years will be shaped by execution on capex and ramp-up. With more than ₹3,000 crore planned over FY27 and FY28, the key questions are utilization, asset turnover normalization toward the 1.1x target, and sustaining EBITDA margins above 30 percent as guided. For now, the direction is supportive: leverage is contained at 1.3x net debt to EBITDA, cash flows strengthened in FY26, and the company is adding capacity in large-scale API, fermentation, and advanced modalities where customer qualification and trust matter.

If Laurus continues to convert its pipeline into commercial supply and improves utilization across newly built assets, the presentation’s central theme holds together: strong execution today, and investing for long-term growth with a broader platform than it had at any point in its last decade.